IMR Press / FBL / Volume 19 / Issue 1 / DOI: 10.2741/4201

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

CD38 and bone marrow microenvironment
Show Less
1 Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino Medical School, Torino, Italy
2 Department of Bioscences, University of Parma, Parma, Italy
3 Anatomia e Istologia patologica, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy
4 Hematology and Blood and Marrow Transplantation (BMT) Center, University of Parma, Parma, Italy
5 Department of Orthopedics and Traumatology, Citta della Salute e della Scienza Hospital, Torino, Italy
6 Laboratory of Oncology, Department of Experimental and Laboratory Medicine, Istituto Giannina Gaslini, Genova, Italy
7 Centro di Ricerca in Medicina Sperimentale (CeRMS), University of Torino Medical School, Torino, Italy
8 Transplantation Immunology Service, Citta della Salute e della Scienza Hospital, Torino, Italy
Front. Biosci. (Landmark Ed) 2014, 19(1), 152–162;
Published: 1 January 2014

This review summarizes the events ruled by CD38 in shaping the bone marrow environment, recapitulating old and new aspects derived from the body of knowledge on the molecule. The disease models considered were myeloma and chronic lymphocytic leukemia (CLL). CD38 has been analyzed considering its twin function as receptor and enzyme, roles usually not considered in clinics, where it is used as a routine marker. Another aspect pertaining basic science concerns the role of the molecule as a member of an ectoenzyme network, potentially metabolizing soluble factors not yet analyzed (e.g., NAD+, ATP, NAM) or influencing hormone secretion (e.g., oxytocin). The last point is focused on the use of CD38 as a target of an antibody-mediated therapeutic approach in myeloma and CLL. A recent observation is that CD38 may run an escape circuit leading to the production of adenosine. The generation of local anergy may be blocked by using anti-CD38 antibodies. Consequently, not only might CD38 be a prime target for mAb-mediated therapy, but its functional block may contribute to general improvement in cancer immunotherapy and outcomes.

Bone marrow
Multiple myeloma
Back to top